Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Effect of the Plasticizer DEHP in Blood Collection Bags on Human Plasma Fraction Unbound Determination for Alpha-1-Acid Glycoprotein (AAG) Binding Drugs.

Ingram N, Dishinger C, Wood J, Hutzler JM, Smith S, Huskin M.

AAPS J. 2018 Nov 16;21(1):5. doi: 10.1208/s12248-018-0276-8.

PMID:
30446887
2.

Assessment of the Biotransformation of Low-Turnover Drugs in the HยตREL Human Hepatocyte Coculture Model.

Burton RD, Hieronymus T, Chamem T, Heim D, Anderson S, Zhu X, Hutzler JM.

Drug Metab Dispos. 2018 Nov;46(11):1617-1625. doi: 10.1124/dmd.118.082867. Epub 2018 Aug 22.

PMID:
30135244
3.

Discovery and optimization of oxadiazole-based FLAP inhibitors.

Bartolozzi A, Abeywardane A, Bosanac T, Broadwater JA, Chen Z, Hutzler JM, Huber JD, Nemoto P, Olague A, Riether D, Simpson T, Takahashi H, Wu L, Zhang Y, Zindell RM.

Bioorg Med Chem Lett. 2017 Oct 15;27(20):4652-4659. doi: 10.1016/j.bmcl.2017.09.007. Epub 2017 Sep 8.

PMID:
28927794
4.

A novel in vitro allometric scaling methodology for aldehyde oxidase substrates to enable selection of appropriate species for traditional allometry.

Crouch RD, Hutzler JM, Daniels JS.

Xenobiotica. 2018 Mar;48(3):219-231. doi: 10.1080/00498254.2017.1296208. Epub 2017 Mar 10.

6.

Low-Turnover Drug Molecules: A Current Challenge for Drug Metabolism Scientists.

Hutzler JM, Ring BJ, Anderson SR.

Drug Metab Dispos. 2015 Dec;43(12):1917-28. doi: 10.1124/dmd.115.066431. Epub 2015 Sep 11. Review.

PMID:
26363026
7.

Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).

Takahashi H, Riether D, Bartolozzi A, Bosanac T, Berger V, Binetti R, Broadwater J, Chen Z, Crux R, De Lombaert S, Dave R, Dines JA, Fadra-Khan T, Flegg A, Garrigou M, Hao MH, Huber J, Hutzler JM, Kerr S, Kotey A, Liu W, Lo HY, Loke PL, Mahaney PE, Morwick TM, Napier S, Olague A, Pack E, Padyana AK, Thomson DS, Tye H, Wu L, Zindell RM, Abeywardane A, Simpson T.

J Med Chem. 2015 Feb 26;58(4):1669-90. doi: 10.1021/jm501185j. Epub 2015 Feb 11.

PMID:
25671290
8.

Cynomolgus monkey as a surrogate for human aldehyde oxidase metabolism of the EGFR inhibitor BIBX1382.

Hutzler JM, Cerny MA, Yang YS, Asher C, Wong D, Frederick K, Gilpin K.

Drug Metab Dispos. 2014 Oct;42(10):1751-60. doi: 10.1124/dmd.114.059030. Epub 2014 Jul 17.

PMID:
25035284
9.

Aldehyde oxidase activity in donor-matched fresh and cryopreserved human hepatocytes and assessment of variability in 75 donors.

Hutzler JM, Yang YS, Brown C, Heyward S, Moeller T.

Drug Metab Dispos. 2014 Jun;42(6):1090-7. doi: 10.1124/dmd.114.057984. Epub 2014 Apr 8.

PMID:
24713130
10.

Strategies for a comprehensive understanding of metabolism by aldehyde oxidase.

Hutzler JM, Obach RS, Dalvie D, Zientek MA.

Expert Opin Drug Metab Toxicol. 2013 Feb;9(2):153-68. doi: 10.1517/17425255.2013.738668. Epub 2012 Dec 12. Review.

PMID:
23231678
11.

Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems.

Albaugh DR, Fullenwider CL, Fisher MB, Hutzler JM.

Drug Metab Dispos. 2012 Jul;40(7):1336-44. doi: 10.1124/dmd.112.044644. Epub 2012 Apr 9.

PMID:
22490230
12.

Characterization of aldehyde oxidase enzyme activity in cryopreserved human hepatocytes.

Hutzler JM, Yang YS, Albaugh D, Fullenwider CL, Schmenk J, Fisher MB.

Drug Metab Dispos. 2012 Feb;40(2):267-75. doi: 10.1124/dmd.111.042861. Epub 2011 Oct 26.

PMID:
22031625
13.

Discovery of ((1S,3R)-1-isopropyl-3-((3S,4S)-3-methoxy-tetrahydro-2H-pyran-4-ylamino)cyclopentyl)(4-(5-(trifluoromethyl)pyridazin-3-yl)piperazin-1-yl)methanone, PF-4254196, a CCR2 antagonist with an improved cardiovascular profile.

Hughes RO, Rogier DJ, Devraj R, Zheng C, Cao G, Feng H, Xia M, Anand R, Xing L, Glenn J, Zhang K, Covington M, Morton PA, Hutzler JM, Davis JW 2nd, Scherle P, Baribaud F, Bahinski A, Mo ZL, Newton R, Metcalf B, Xue CB.

Bioorg Med Chem Lett. 2011 May 1;21(9):2626-30. doi: 10.1016/j.bmcl.2011.01.034. Epub 2011 Jan 15.

PMID:
21315584
14.

Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator?

Linder CD, Renaud NA, Hutzler JM.

Drug Metab Dispos. 2009 Jan;37(1):10-3. doi: 10.1124/dmd.108.024075. Epub 2008 Oct 20.

PMID:
18936109
15.

Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection.

Hutzler JM, Balogh LM, Zientek M, Kumar V, Tracy TS.

Drug Metab Dispos. 2009 Jan;37(1):59-65. doi: 10.1124/dmd.108.023358. Epub 2008 Oct 6.

16.

Assessment of the metabolism and intrinsic reactivity of a novel catechol metabolite.

Hutzler JM, Melton RJ, Rumsey JM, Thompson DC, Rock DA, Wienkers LC.

Chem Res Toxicol. 2008 May;21(5):1125-33. doi: 10.1021/tx700429v. Epub 2008 Apr 12.

PMID:
18407675
17.

Visible spectra of type II cytochrome P450-drug complexes: evidence that "incomplete" heme coordination is common.

Locuson CW, Hutzler JM, Tracy TS.

Drug Metab Dispos. 2007 Apr;35(4):614-22. Epub 2007 Jan 24.

PMID:
17251307
18.

Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: Evidence for complex heme interactions.

Hutzler JM, Melton RJ, Rumsey JM, Schnute ME, Locuson CW, Wienkers LC.

Chem Res Toxicol. 2006 Dec;19(12):1650-9.

PMID:
17173379
20.

Influence of fluorescent probe size and cytochrome b5 on drug-drug interactions in CYP2C9.

Hummel MA, Tracy TS, Hutzler JM, Wahlstrom JL, Zhou Y, Rock DA.

J Biomol Screen. 2006 Apr;11(3):303-9. Epub 2006 Feb 20.

PMID:
16490777
21.

Catalytic turnover of pyrene by CYP3A4: evidence that cytochrome b5 directly induces positive cooperativity.

Jushchyshyn MI, Hutzler JM, Schrag ML, Wienkers LC.

Arch Biochem Biophys. 2005 Jun 1;438(1):21-8. Epub 2005 Mar 5.

PMID:
15910734
22.

Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures.

Komoroski BJ, Zhang S, Cai H, Hutzler JM, Frye R, Tracy TS, Strom SC, Lehmann T, Ang CY, Cui YY, Venkataramanan R.

Drug Metab Dispos. 2004 May;32(5):512-8.

PMID:
15100173
24.

Effect of carbonate anion on cytochrome P450 2D6-mediated metabolism in vitro: the potential role of multiple oxygenating species.

Hutzler JM, Powers FJ, Wynalda MA, Wienkers LC.

Arch Biochem Biophys. 2003 Sep 15;417(2):165-75.

PMID:
12941298
25.

In vitro metabolism of clindamycin in human liver and intestinal microsomes.

Wynalda MA, Hutzler JM, Koets MD, Podoll T, Wienkers LC.

Drug Metab Dispos. 2003 Jul;31(7):878-87.

PMID:
12814964
26.

Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues.

Hutzler JM, Walker GS, Wienkers LC.

Chem Res Toxicol. 2003 Apr;16(4):450-9.

PMID:
12703961
27.

Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations.

Hutzler JM, Wienkers LC, Wahlstrom JL, Carlson TJ, Tracy TS.

Arch Biochem Biophys. 2003 Feb 1;410(1):16-24.

PMID:
12559973
28.

Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements.

Hutzler JM, Kolwankar D, Hummel MA, Tracy TS.

Drug Metab Dispos. 2002 Nov;30(11):1194-200.

PMID:
12386124
29.

Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.

Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmann LJ.

Drug Metab Dispos. 2002 Apr;30(4):385-90.

PMID:
11901091
30.

Atypical kinetic profiles in drug metabolism reactions.

Hutzler JM, Tracy TS.

Drug Metab Dispos. 2002 Apr;30(4):355-62. Review. No abstract available.

PMID:
11901086
31.

Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone.

Hutzler JM, Frye RF, Korzekwa KR, Branch RA, Huang SM, Tracy TS.

Eur J Pharm Sci. 2001 Aug;14(1):47-52.

PMID:
11457649
32.

Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model.

Hutzler JM, Hauer MJ, Tracy TS.

Drug Metab Dispos. 2001 Jul;29(7):1029-34. Erratum in: Drug Metab Dispos 2001 Aug;29(8):1171.

PMID:
11408370
33.

Sensitive and specific high-performance liquid chromatographic assay for 4'-hydroxyflurbiprofen and flurbiprofen in human urine and plasma.

Hutzler JM, Frye RF, Tracy TS.

J Chromatogr B Biomed Sci Appl. 2000 Nov 10;749(1):119-25.

PMID:
11129071
34.

Single dose pharmacokinetics of syrup of ipecac.

Scharman EJ, Hutzler JM, Rosencrance JG, Tracy TS.

Ther Drug Monit. 2000 Oct;22(5):566-73.

PMID:
11034262

Supplemental Content

Loading ...
Support Center